This acquisition allows versatile analyses of pharmaceutical drug substances and drug products for both small molecules and large biologics.
WEST LAFAYETTE, Ind., Feb. 27, 2025 /PRNewswire/ — Liquid chromatography coupled with High-Resolution Accurate Mass Spectrometry (LC-HRAMS) is a powerful and flexible technique for the analyses of pharmaceutical drug substances and drug products. The technique separates and identifies analytes based on their retention times, mass-to-charge ratios, and parent ion fragmentation patterns. LC-HRAMS allows for the confident identification and quantitation of small molecule compounds, as well as large biologic molecules and polymers. Tandem HRAMS (MS/MS) is particularly useful for characterization and structural elucidation of unknown compounds in complex matrices, as well as the sequencing of proteins and peptides.
Improved Pharma has installed and operationally qualified a SCIEX TripleTOF® 6600 coupled to a SCIEX Exigent UHPLC system with UV detection. This system is a classic QTOF configuration comprised of a quadrupole mass filter collision cell, and Time of Flight mass filter. The TripleTOF® 6600 platform is equipped with ESI, APCI, and nano-spray ion sources, as well as an optional SelexION ion mobility stage. This instrument merges the very high resolving power of a Time of Flight (TOF) mass spectrometer with the high selectivity offered by MS/MS. The system is also sensitive enough for quantitative analyses of impurities or degradants at trace levels (ppm to ppb).
About Improved Pharma: Improved Pharma is a research, consulting, and information company dedicated to improving pharmaceutical methods, formulations, and processes. Services include solid-state form studies, formulation design, synchrotron techniques, analytical testing, and expert consulting for the development and defense of intellectual property matters. The company was founded in 2006 by Stephen and Sarah Byrn, who also founded SSCI
Media Contact
Pam Smith, Improved Pharma, (765) 463-9951, info@improvedpharma.com, https://improvedpharma.com/
SOURCE Improved Pharma
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…